Eicosanoids pp 165-182 | Cite as

Leukotriene Antagonists and Synthetase Inhibitors; Clinical Applications in the Treatment of Bronchial Asthma

  • G. C. Folco
  • C. Buccellati
  • T. Testa
  • M. Bolla
  • A. Sala
Chapter
Part of the NATO ASI Series book series (NSSA, volume 283)

Abstract

Asthma is a complex disease with the following characteristics: (1) airway obstruction that is reversible (but not completely so in some patients) either spontaneously or with treatment; (2) airway inflammation; and (3) increased airway responsiveness to a variety of stimuli (National Heart, Lung, and Blood Institute; National Asthma Education Program; Guidelines for the diagnostic and management of asthma, March 11, 1991). Recent observations in both human subjects and animal models suggest that the abnormalities of asthma are manifestations of airway inflammation that is a key factor even in patients with asthma at a clinically early stage (Laitinen et al., 1993).

Keywords

Asthmatic Subject Late Asthmatic Response Eicosatetraenoic Acid Human Bronchus LTA4 Hydrolase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adelroth, E., Morris, M.M., Hargreave, F.E., O’Byrne, P.M., 1986, Airway responsiveness to LTC4 and D4 and to methacholine in patients with asthma and normal controls, N. Engl. J. Med. 315:480–484.PubMedCrossRefGoogle Scholar
  2. Augstein, J., Farmer, J.B., Lee, T.B., Sheard, P., Tattersall, M.L., 1973, Selective inhibitor of slow reacting substance of anaphylaxis, Nature [New Biol.] 245:215–217.CrossRefGoogle Scholar
  3. Barnes, N.C., Evans, J., Zarkzewski, J.T., Piper, P.J., Costello, J.F., 1989, A critical evaluation of the clinical rilevance of leukotrienes in bronchial asthma, Agents Actions Suppl. 28:123–133.Google Scholar
  4. Barnes, P., 1987, Neuropeptides in the lung: localization, function and pathophysiologic implications, J. Allergy Clin. Immunol. 79:285–295.PubMedCrossRefGoogle Scholar
  5. Batt, D.G., 1992, 5-lipoxygenase inhibitors adn their anti-inflammatory activities, in Progress in Medicinal Chemistry, G.P. Ellis, D.K. Luscombe eds., Elsevier Science Publishers B.V., vol. 29 pp 1–63.Google Scholar
  6. Bisgaard, H., Groth, S., Madsen, F., 1985, Bronchial hyperreactivity to leukotriene D4 and histamine in exogenous asthma, Br. Med. J. 290:1468–1471.CrossRefGoogle Scholar
  7. Bisgaard, H., Kristensen, J., Sondergaard, J., 1982, The effect of leukotriene C4 and D4 on cutaneous blood flow in humans, Prostaglandins 23:797–801.PubMedGoogle Scholar
  8. Bisgaard, H., Poulson, L., Sondergaard, I., 1987, Nebulisation and selective deposition of LTD4 in human lungs, Allergy 42:336–342.PubMedCrossRefGoogle Scholar
  9. Borgeat, P., Samuelsson, B., 1979, Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids, Proc. Natl. Acad. Sci. U.S.A. 76: 3213–3217.PubMedCrossRefGoogle Scholar
  10. Botto, A., DeLepeleire, I., Rochette, F., Reiss, T.F., Zhang, J., Kundu, S., Decramer, M., 1994, MK-0476 causes prolonged, potent, LTD4 receptor antagonism in the airways of asthmatics, Am. J. Resp. Crit. Care Med. 149:A465.Google Scholar
  11. Buckner, C.K., Krell, R.D., Laravuso, R.B., Coursin, D.B., Bernstein, P.R., Will, J.A., 1986, Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4, J. Pharmacol. Exp. Ther. 237:558–562.PubMedGoogle Scholar
  12. Camp, R.D.R., Greaves, M.W., 1987, Inflammatory mediators in skin, Br. Med. Bull. 43:401–414.PubMedGoogle Scholar
  13. Carry, M., Korley, V., Willerson, J.T., Weigelt, L., Ford-Hutchinson, A.W., Tagari, P., 1992, Increased urinary excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation, Circulation 85:230–236.Google Scholar
  14. Carter, G.W., Young, P.R., Albert, D.H., Bouska, J., Dyer, R., Bell, R.L., Summers, J.D., Brooks, D.W., 1991, 5-lipoxygenase inhibitory activity of Zileuton, J. Pharmacol. Exp. Ther. 256:929–937.PubMedGoogle Scholar
  15. Christie, P.E., Smith, C.M., Lee, T.H., 1991b, The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma, Am. Rev. Respir. Dis. 144:957–958.PubMedCrossRefGoogle Scholar
  16. Christie, P.E., Spur, B.W., Lee, T.H., 1991a, The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4-and leukotriene E4-induced bronchoconstriction in subjects with asthma, J. Allergy Clin. Immunol. 88:193–198.PubMedCrossRefGoogle Scholar
  17. Cockcroft, D.W., Ruffin, R.E., Dolovich, J., Hargreave, F.E., 1977, Allergen-induced increase in non-allergic bronchial reactivity, Clin. Allergy 7:503–513.PubMedCrossRefGoogle Scholar
  18. Coles, S.J., Neill, K.H., Reid, L.M., et al., 1983, Effects of leukotriene C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa, Prostaglandins 25:155–170.PubMedGoogle Scholar
  19. Cunningham, F., 1990, Lipid mediators in inflammatory skin disorders, J. Lipid Mediators 2:61–74Google Scholar
  20. Cuss, F.M., Dixon, C.M., Barnes, P.J., 1986, Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man, Lancet 2:189–192.PubMedCrossRefGoogle Scholar
  21. Dahlén, B., Margolskee, D.J., Zetterström, O., Dahlén, S.-E., Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects, Thorax 48:1205-1210.Google Scholar
  22. Dahlén, B., Zetterström, O., Björck, T., Dahlén, S.-E., 1994, The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics, Eur. Respir. J. 7:324–331.PubMedCrossRefGoogle Scholar
  23. Dahlén, S.E., Hedqvist, P., Hammarström, S., Samuelsson, B., 1980, Leukotrienes are potent constrictor of human bronchi, Nature 228:484–486.CrossRefGoogle Scholar
  24. Davidson, A.B., Lee, T.H., Scanion, P.D., Solway, J., McFadden, E.R. jr, Ingram, R.H. jr, Corey, E.J., Austen, K.F., Drazen, J.M., 1987, Bronchocostrictor effects of leukotriene E4 in normal and asthmatic subjects, Am. Rev. Respir. Dis. 135:333–337.PubMedGoogle Scholar
  25. Dennis, E.A., Ackermann, E.J., Deems, R.A., Reynolds, L.J., 1995, Multiple forms of PLA2 in macrophages capable of arachidonic acid release for eicosanoid biosynthesis, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson, P.W. Ramwell, R. Paoletti, G.C. Folco, E. Granström and S. Nicosia eds., Raven Press, New York, vol. 23 pp. 75–80.Google Scholar
  26. Dixon, R.A.F., Diehl, R.E., Opas, E., Rands, E., Vickers, P.J., Evans, J.F., Gillard, J.W., Miller, D.K., 1990, Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis, Nature 343:282–284.PubMedCrossRefGoogle Scholar
  27. Drazen, J.M., Austen, K.F, 1987, Leukotrienes and airway responses, Am. Rev. Respir. Dis. 136:985–998.PubMedCrossRefGoogle Scholar
  28. Dugas, B., Paul-Eugene, N., Cairns, J., Gordon, J., Calenda, A., Mencia-Huerta, J.M., Braquet, P., 1990, Leukotriene B4 potentiates the expression and release of FCεRII/CD23, and proliferation and differentiation of human B lynfocytes induced by IL-4, J. Immunol. 145:3406.PubMedGoogle Scholar
  29. Dutoit, J.I., Salome, C.M., Woolcock, A.J., 1987, Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not, Am. Rev. Respir. Dis. 136:1174–1178.PubMedCrossRefGoogle Scholar
  30. Ellis, J.L., Undem, B.J., 1994, Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi, Am. J. Respir. Crit. Care Med. 149:118–122.PubMedCrossRefGoogle Scholar
  31. Empey, D.W., Laitinen, L.A., Jacobs, L., Gold, W.M., Nadel, J. A., 1976, Mechanism of bronchial hyperreactivity in normal subjects following upper respiratory tract infection, Am. Rev. Respir. Dis. 113:131–139.PubMedGoogle Scholar
  32. Feinmark, S.J., Cannon, P.J., 1986, Endothelial cell leukotriene C4 synthesis results from intracellular trasfer of leukotriene A4synthetized by polymrphonuclear leukocytes, J. Biol. Chem. 261: 16466–16472.PubMedGoogle Scholar
  33. Findlay, S.R., Barden, J.M., Easley, C.B., Glass, M., 1992, Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma, J. Allergy Clin. Immunol., 89:1040–1045.PubMedCrossRefGoogle Scholar
  34. Fitzpatrick, F., Liggett, W., McGee, J., Bunting, S., Morton, D., Samuelsson, B., 1984, Metabolism of leukotriene A4 by human erytrocytes, J. Biol. Chem. 259:11403–11407.PubMedGoogle Scholar
  35. Fitzsimmons, B.J., Rokach, J., 1989, in Leukotrienes and Lipoxygenases, J. Rokach ed., Elsevier, Amsterdam, pp. 427–502.Google Scholar
  36. Ford-Hutchinson, A.W., 1990, Regulation of the production and action of leukotrienes by MK-571 and MK-886, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson, P.W. Ramwell, R. Paoletti, G.C. Folco, E. Granström eds., Raven Press, New York, vol. 21 App. 9–16.Google Scholar
  37. Ford-Hutchinson, A.W., Bray, W.M., Doig, M.V., Shipley, M.E., Smith, M.J.H., 1980, Leukotriene B, a potent chemokinetic and aggregating substance released from PMN leukocytes, Nature 286:264–265.PubMedCrossRefGoogle Scholar
  38. Fruchtmann, R., Mohrs, K.-H., Hatzelmann, A., Raddatz, S., Fugmann, B., Junge, B., Horstmann, H., Müller-Peddinghaus, R., 1993, In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis, Agents Actions 38:188–195.PubMedCrossRefGoogle Scholar
  39. Gaddy J.N., Margolskee, D.J., Bush, R.K., Williams, V.C., Busse, W.W., 1992, Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma, Am. Rev. Respir. Dis. 146:358–363.PubMedCrossRefGoogle Scholar
  40. Goetzl, E.J., Pickett, W.C., 1980, The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs), J. Immunol. 125:1789.PubMedGoogle Scholar
  41. Golden, J.A., Nadel, J.A., Boushey, H.A., 1978, Bronchial hyperirritability in healty subjects after exposure to ozone, Am. Rev. Respir. Dis 118:287–294.PubMedGoogle Scholar
  42. Hannah, C.J., Bach, M.K., Pare, P.D. et al., 1981, Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro, Nature 290:343–344.CrossRefGoogle Scholar
  43. Hardy, C.C., Robinson, C., Tattersfield, A.E., Holgate, S.T., 1984, The bronchocostrictor effect of inhaled prostaglandin D2 in normal and asthmatic men, N. Engl. J. Med. 311:209–213.PubMedCrossRefGoogle Scholar
  44. Hargreave, F.E., Ryan, G., Thomson, N.C., et al., 1981, Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance, J. Allergy Clin. Immunol. 68:347–355.PubMedCrossRefGoogle Scholar
  45. Hatzelmann, A., Goossens, J., Fruchtmann, R., Mohrs, K.-H., Raddatz, S., Müller-Peddinghaus, R., 1994, Inversely-correlated inhibition of human 5-lipoxy genase activity by BAY X1500 and other quinoline derivates in intact cells and a cell-free system-Implications for the function of 5-lipoxygenase activating protein, Biochem. Pharmacol. 47(n°12):2259–2268.PubMedCrossRefGoogle Scholar
  46. Holroyde, M.C., Altounyan, R.E.C., Cole, M., Dixon, M., Elliot, E.V., 1981, Bronchocostriction produced in man by leukotrienes C and D, Lancet 2: 17–18.PubMedCrossRefGoogle Scholar
  47. Hui, K.P., Taylor, I.K., Taylor, G.W, Rubin, P., Kesterson, J., Barnes, N.C., Barnes, P.J., 1991, Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after challenge in asthmatic patients, Thorax 46:184–189.PubMedCrossRefGoogle Scholar
  48. Israel, E., Dermarkarian, R., Rosemberg, M., Sperling, R., Taylor, G., Rubin, P., Drazen, J.M., 1990, The effect of a 5-lipoxigenase inhibitor on asthma induced by cold, dry air, N. Engl. J. Med. 323:1740–1744.PubMedCrossRefGoogle Scholar
  49. Israel, E., Fischer, A.R., Rosemberg, M.A., Lilly, CM., Callery, J.C., Shapiro, J., Cohn, J., Rubin, P., Drazen, J.M., 1993a, The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin, Am. Rev. Respir. Dis. 148:1447–1451.PubMedCrossRefGoogle Scholar
  50. Israel, E., Rubin, P., Kemp, J.P., Grossman, J., Pierson, W., Siegel, S.C., Tinkelman, D., Murray, J.J., Busse, W., Segal, A.T., Fish, J., Kaiser, H.B., Ledford, D., Wenzel, S., Rosenthal, R., Cohn, J., Lanni, C., Pearlman, H., Karahalios, P., Drazen, J.M., 1993b, The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma, Ann. Intern. Med. 119:1059–1066.PubMedCrossRefGoogle Scholar
  51. Jones, T.R., Champion, E., Charette, L., Ford-Hutchinson, A.W., Labelle, M., Leblanc, Y., Lord, A., Masson, P., McAuliffe, M., McFerlane, C.S., Metters, K.M., Ouimet, N., Pickett, C., Piechuta, H., Rochette, C., Rodger, I.W., Sawyer, N., Wiang, Y.B., Young, R.N., Zamboni, R., 1994, Pharmacology of MK-0476, a potent and selective leukotriene D4-receptor antagonist, Am. J. Resp. Crit. Care Med. 149:A463.Google Scholar
  52. Jones, T.R., Davis, C., Daniel, E.E., 1982, Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle, Can. J. Physiol. Pharmacol. 60:638–643.PubMedCrossRefGoogle Scholar
  53. Kennedy, N.P., Keeling, P.W.N., 1987, Review: lipoxygenase inhibitors and the gut, Aliment. Pharmacol. Ther. 1:263–272.PubMedCrossRefGoogle Scholar
  54. Kips, J.G., Joos, G.F., De Lepeleire, I., Margolskee, D.J., Buntinx, A., Pauwels, R.A., Van der Straeten, M.E., 1991, MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human, Am. Rev. Respir. Dis. 144:617–621.PubMedCrossRefGoogle Scholar
  55. Kohno, S., Tsuzuike, N., Yamamura, H., Nabe, T., Horiba, M., Ohata, K., 1993, Important role of peptido leukotrienes (p-LTs) in the resting tonus of isolated human bronchi, Japan. J. Pharmacol. 62:351–355.CrossRefGoogle Scholar
  56. Krell, R.D., Aharony, D., Buckner, C.K., Keith, R.A., Kusner, E.J., Snyder, D.W., Bernstein, P.R., Matassa, V.G., Yee, Y.K., Brown, F.J., Hesp, B., Giles, R.E., 1990, The preclinical pharmacology of ICI 204, 219. A peptide luekotriene antagonist, Am. Rev. Respir. Dis. 141:978–987.PubMedCrossRefGoogle Scholar
  57. Laitinen, L.A., Laitinen, A., Haahtela, T., 1993, Airway mucosal inflammation even in patients with newly diagnosed asthma, Am. Rev. Respir. Dis. 147:697–704.PubMedCrossRefGoogle Scholar
  58. Lammers, J.-W.J., Van Daele, P., Van den Elshout, F.M.J., Decramer, M., Buntinx, A., De Lepeleire, I., Friedman B., 1992, Brochodilator properties of an inhaled leukotriene D4 antagonist (Verlukast—MK-0679) in asthmatic patients, Pulm. Pharmacol. 5:121–125.PubMedCrossRefGoogle Scholar
  59. Lewis, R.A., Austen, K.F., 1984, TheBiologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology, J. Clin. Invest. 73:889–897.PubMedCrossRefGoogle Scholar
  60. Lewis, R.A., Austen, K.F., Soberman, R.J., 1990, Leukotrienes and other products of the 5-lipoxygenase pathway-Biochemistry and relation to pathobiologi in human diseases, N. Engl. J. Med. 323:645–655PubMedCrossRefGoogle Scholar
  61. Lewis, R.A., Robin, J.L., 1985, Arachidonic acid derivatives as mediators of asthma, J. Allergy Clin. Immunol. 76:259–264.PubMedCrossRefGoogle Scholar
  62. Maclouf, J., Murphy, R.C., Henson, P., 1989, Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells, Blood 74:703–707.PubMedGoogle Scholar
  63. Makker, H.K., Lau, L.C., Thomson, H.W., Binks, S.M., Holgate, S.T., 1993, The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma, Am. Rev. Respir. Dis. 147:1413–1418.PubMedCrossRefGoogle Scholar
  64. Manning, P.J., Watson, R.M., Margolskee, D.J., Williams, V.C., Schwartz, J.I., O’Byrne, P.M., 1990, Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist, N. Engl. J. Med. 323:1736–1739.PubMedCrossRefGoogle Scholar
  65. Mapp, C.E., Di Giacomo, G.R., Omini, C., Broseghini, C., Fabbri, L.M., 1986, Late, but non early, asthmatic reactions induced by toluene-diisocyanate are associated with increased airway responsiveness to methacholine, Eur. J. Respir. Dis. 69:276–284.PubMedGoogle Scholar
  66. Margolskee, D.J., 1991, Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist, Ann. N.Y. Acad. Sci. 629:148–156.PubMedCrossRefGoogle Scholar
  67. Maron, Z., Shelhamer, J.H., Bach, M.K., et al., 1982, Slow reacting substances LTC4 and D4 increase the release of mucus from human airways in vitro, Am. Rev. Respir. Dis. 126: 449–451.Google Scholar
  68. Müller-Peddinghaus, R., Kohlsdorfer, C., Theisen-Popp, P., Fruchtmann, R., Perzborn, E., Beckermann, B., Bühner, K., Ahr, H.-J., Mohrs, K.-H., 1993 BAY X1500, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics, J. Pharmacol. Exp. Ther. 267:51–57PubMedGoogle Scholar
  69. Murphy, R.C., Hammarström, S., Samuelsson, B., 1979, Leukotriene C: a slow-reacting substance from murine mastocytoma cells, Proc. Natl. Acad. Sci. U.S.A. 76:4275–4279.PubMedCrossRefGoogle Scholar
  70. Nasser, S.M.S., Bell, G.S., Foster, S., Spruce, K.E., MacMillan R., Williams, A.J., Lee, T.H., Arm, J.P., 1994b, Effect of the 5-lipoxygenase inhibitor ZD 2138 on aspirin-induced asthma, Thorax 49:749–756.PubMedCrossRefGoogle Scholar
  71. Nasser, S.M.S., Bell, G.S., Hawksworth, R.J., Spruce, K.E., MacMillan R., Williams, A.J., Lee, T.H., Arm, J.P., 1994a, Effect of the 5-lipoxygenase inhibitor ZD 2138 on allergen-induced early and late asthmatic responses, Thorax 49:743–748.PubMedCrossRefGoogle Scholar
  72. Nathan, R.A., Glass, M., Minkwitz, M.C., 1994, Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma, Chest 105:483–488.PubMedCrossRefGoogle Scholar
  73. O’Shaughnessy, K.M., Taylor, I.K., O’Connor, B., O’Connell, F., Thomson, H., Dollery, C.T., 1993, Potent leukotriene D4 receptor antagonist ICI 204, 219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction, Am. Rev. Respir. Dis. 147:1431–1435.PubMedCrossRefGoogle Scholar
  74. Orning, L., Hammarström, S., Samuelsson, B., 1980, Leukotriene D4: a slow reacting substance from rat basophilic leukemia cells, Proc. Natl. Acad. Sci. U.S.A. 77:2014–2017.PubMedCrossRefGoogle Scholar
  75. Osborn, R.R., Hay, D.W.P., Wasserman, M.A., Torphy T. J., 1992, SK&F 104353, a selective leukotriene receptor antagonist, inhibits LTD4-and antigen-induced bronchoconstriction in cynomolgus monkeys, Pulm. Pharmacol. 5(3): 153–157.PubMedCrossRefGoogle Scholar
  76. Piacentini, G.L., Kaliner, M.A., 1991, The potential roles of leukotrienes in bronchial asthma, Am. Rev. Respir. Dis. 143:S96–S99.PubMedCrossRefGoogle Scholar
  77. Pierson, W.E., LaForce, C.F., Bell, T.D., MacCosbe, P.E., Sykes, R.S., Tinkelman, D., 1990, Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma, J. Allergy Clin. Immunol. 85:618–626.PubMedCrossRefGoogle Scholar
  78. Platts-Mills, T.A.E., Mitchell, E.B., Nock, P., Tovey, E.R., Moszoro, H., Wilkins, S.R., 1982, Reduction of bronchial hyperreactivity during prolonged allergen avoidance, Lancet 2:675–678.PubMedCrossRefGoogle Scholar
  79. Rådmark, O., Zhang, Y.-Y., Hammarberg, T., Lind, B., Hamberg, M., Brungs, M., Steinhilber, D., Samuelsson, B., 1995, 5-Lipoxygenase: structure and stability of recombinant enzyme, regulation in Mono Mac 6 cells, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson, P.W. Ramwell, R. Paoletti, G.C. Folco, E. Granström and S. Nicosia eds., Raven Press, New York, vol. 23 pp. 1–9.Google Scholar
  80. Raud, J., Dahlén, S.E., Sydbom, A., Lindbom, L., Hedqvist, P., 1988, Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release, Proc. Natl. Acad. Sci. U.S.A. 85:2315–2319.PubMedCrossRefGoogle Scholar
  81. Robuschi, M., Riva, E., Fuccella, L.M., Vida, E., Barnabe, R., Rossi, M., Gambaro, G., Spagnotto, S., Bianco, S., 1992, Prevention of exercise-induced bronchoconstristion by a new leukotriene antagonist (SK&F 104353), Am. Rev. Respir. Dis. 145:1285–1288.PubMedCrossRefGoogle Scholar
  82. Rola-Pleszczynski, M., Borgeat, P., Sirois, P., 1982, Leukotriene B4 induces human suppressor lymphocytes, Biochem. Biophys. Res. Commun. 108:1531–1537.PubMedCrossRefGoogle Scholar
  83. Sala, A., Rossoni, G., Buccellati, C., Berti, F., Folco, G.C., Maclouf, J., 1993, Formation of sulfidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit, Br. J. Pharmacol. 110:1206–1212.PubMedCrossRefGoogle Scholar
  84. Sala, A., Voelkel, N., Maclouf, J., Murphy, R.C., 1990, Leukotriene E4 elimination and metabolism in normal human subjects, J. Biol. Chem. 265(35):21771–21778.PubMedGoogle Scholar
  85. Samuelsson, B., Rouzer, C.A., Matsumoto, T., 1987, Human leukocyte 5-lipoxygenase: an enzyme possessing dual enzymatic activities and a multicomponent regulatory system, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson, R. Paoletti, P.W. Ramwell eds., Raven Press, New York, vol. 17A pp.1–11.Google Scholar
  86. Sheppard, D., Wong, W.S., Uehora, C.F., Nadel J.A., Boushey, H.A., 1980, Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide, Am. Rev. Respir. Dis. 122:873–878.PubMedGoogle Scholar
  87. Smith, L.J., Geller, S., Ebright, L., Glass, M., Thyrum, P.T., 1990, Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219, Am. Rev. Respir. Dis. 141:988–992.PubMedCrossRefGoogle Scholar
  88. Smith, L.J., Greenberger, P.A., Patterson, R., Krell, R.D., Bernstein P.R., 1985, The effect of inhaled leukotriene D4 in humans, Am. Rev. Respir. Dis. 131:368–372.PubMedGoogle Scholar
  89. Smith, M.J.H., Ford-Hutchinson, A.W., Bray, M.A., 1980, Leukotriene B: a potential mediator of inflammation, J. Pharm. Pharmacol. 32:517.PubMedCrossRefGoogle Scholar
  90. Snyder, D.W., Krell, R.D., 1984, Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea, J. Pharmacol. Exp. Ther. 231:616–622.PubMedGoogle Scholar
  91. Spector, S.L., Smith, L.J., Glass, M., and ACCOLATE-Asthma Trialists Group, 1994, Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma, Am. J. Respir. Crit. Care Med. 150:618–623.PubMedCrossRefGoogle Scholar
  92. Staerk Laursen, L., Naesdal, J., Bukhave, K., Lauritsen, K., Rask-Madsen, J., 1990, Selective 5-lipoxygenase inhibition in ulcerative colitis, Lancet 335:683–685.CrossRefGoogle Scholar
  93. Szczeklik, A., 1994, Aspirin-induced asthma: an update and novel findings, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, S.E. Dahlén, P. Hedqvist, B. Samuelsson, W.A. Taylor, J. Fritsch eds., Raven Press, New York, vol. 22 pp. 185–198.Google Scholar
  94. Taylor, I.K., O’Shaughnessy, K.M., Fuller, R.W., Dollery, C.T., 1991, Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects, Lancet 337:690–694.PubMedCrossRefGoogle Scholar
  95. Torphy, T.J., Faiferman, I., Gleason, J.G., Hall, R.F., Lewis, M.A., Broom, C., Helfrich, H.M., Newton, J.F., Hay, D.W.P., 1991, The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist, Ann. N.Y. Acad. Sci. 629:157–167PubMedCrossRefGoogle Scholar
  96. Torphy, T.J., Newton, J.F., Wasserman, M.A., Vickery-Clark, L., Osborn, R.R., Bailey, L.S., Yodis, L.A.R, Underwood, D.C., Hay, D.W.R, 1989, The bronchopulmunary pharmacology of Sk&F 104353 in anesthetized guinea pigs: demostration of potent and selective antagonism of responses to peptidoleukotrienes, J. Pharmacol. Exp. Ther. 249:430–437.PubMedGoogle Scholar
  97. Vathenen, A.S., Knox, A.J., Wisniewski, A., Tattersfield, A.E., 1991, Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma, Am. Rev. Respir. Dis. 143:1317–1321.PubMedCrossRefGoogle Scholar
  98. Wahedna, I., Wisniewski, A.S., Tattersfield, A.E., 1991, Effect of Rg 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma, Br. J. Clin. Pharmac. 32:512–515.CrossRefGoogle Scholar
  99. Wanner, A., Sielczak, M., Mella, J.F., et al., 1986, Ciliary responsiveness in allergic and non-allergic airways, J. Appl. Physiol. 60:1967–1971.PubMedGoogle Scholar
  100. Weiss, J.W., Drazen, J.M., McFadden, E.R. jr. et al., 1983, Airway constriction in normal humans produced by inhalation of leukotriene D, JAMA 249:2814–2817.PubMedCrossRefGoogle Scholar
  101. Wetterholm, A., Macchia, L., Haeggstrom, J.Z., 1995, Metal inhibition of LTA4 hydrolase and cellular 5-lipoxygenase activity, in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson, P.W. Ramwell, R. Paoletti, G.C. Folco, E. Granström and S. Nicosia eds., Raven Press, New York, vol. 23 pp. 179–181.Google Scholar
  102. Yamaguchi, T., Kohrogi, H., Honda, I., Kawano, O., Sugimoto, M., Araki, S., Ando, M., 1992, A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro, Am. Rev. Respir. Dis. 146:923–929.PubMedCrossRefGoogle Scholar
  103. Yamamoto, H., Nagata, M., Kuramitsu, K., Tabe, K., Kiuchi, H., Sakamoto, Y., Yamamoto, K., Dohi, Y., 1994, Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078, Am. J. Respir. Crit. Care Med. 150:254–257.PubMedCrossRefGoogle Scholar
  104. Yamaoka, K.A., Claésson, H.-E., Rosén, A., 1989, Leukotriene B4 enhances activation, proliferation, and differentiation of human B lynfocytes, J. Immunol. 143:1996–2000.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • G. C. Folco
    • 1
  • C. Buccellati
    • 1
  • T. Testa
    • 1
  • M. Bolla
    • 1
  • A. Sala
    • 1
  1. 1.Center for Cardiopulmonary Pharmacology, Institute of Pharmacological SciencesUniversity of MilanMilanItaly

Personalised recommendations